Approval · Notice of Compliance 18880 · 2017
ARZERRA: Notice of Compliance 18880
Issued January 17, 2017
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 18880
- Date
- January 17, 2017
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Product monograph update
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ARZERRA | Not yet assigned | — |
Medicinal ingredients
- OFATUMUMAB 20 MG per ML